BUZZ-Precigen rises on long-term data of rare respiratory disease therapy

Reuters
10/13
BUZZ-<a href="https://laohu8.com/S/PGEN">Precigen</a> rises on long-term data of rare respiratory disease therapy

** U.S. biotech firm Precigen's PGEN.O shares rise 5.5% to $3.29 premarket

** Co says its drug Papzimeos showed durable response in adults with recurrent respiratory papillomatosis (RRP), a rare respiratory disease that causes benign tumor growth in the airways

** Durable response means patients stayed symptom-free without needing repeat surgeries for years

** PGEN says 83% of patients with complete response to Papzimeos stayed surgery-free after 3 years

** Co says 95% of patients needed fewer surgeries in year 3 compared to the year before starting Papzimeos

** In August, Papzimeos became the first FDA-approved therapy for adults with RRP

** Up to last close, stock up ~179% YTD

(Reporting by Sahil Pandey)

((Sahil.Pandey@thomsonreuters.com))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10